Ensysce Biosciences, Inc. (ENSC)

Compare

2.6400

+0.1400

+(5.60%)

At close: April 2 at 4:00:01 PM EDT

2.5000

-0.14

(-5.30%)

After hours: April 2 at 6:43:00 PM EDT

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for ...

ACCESS Newswire 2 days ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the ...

ACCESS Newswire 15 days ago

ENSC
+5.60%
ENSCW
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

New York, NY, March 13, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The update note includes information on Ensysce Biosciences’ business model, services, industry, financial results, valuation, and risks. The update note is available below. Ensysce March 2025 Update Note Highlights from the note include: Ensysce Biosciences Advances

GlobeNewswire 20 days ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations

Ensysce Biosciences ( NASDAQ:ENSC ) Full Year 2024 Results Key Financial Results Revenue: US$5.21m (up 134% from FY...

Simply Wall St. 21 days ago

ENSC
+5.60%
ENSCW
ENSC Starts 2025 in Great Shape

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) released its 4Q2024 results that showed a good cash balance of $3.5 million due in large part to the financing activities management has undertaken which we’ve described in earlier reports, as well as a focus on controlling administrative expenses. In 2024, the company announced that it has

Zacks Small Cap Research 22 days ago

ENSCW
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ...

ACCESS Newswire 23 days ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for ...

ACCESS Newswire 28 days ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ: ENSC) CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS, Program Director with Creighton University. The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how "clever chemistry" is being used to introduce safer opioids that are less prone to accidental overdose and abuse.

PR Newswire 30 days ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

SAN DIEGO, CA / ACCESS Newswire / February 5, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for ...

ACCESS Newswire last month

ENSC
+5.60%
ENSCW
When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)?

With the business potentially at an important milestone, we thought we'd take a closer look at Ensysce Biosciences...

Simply Wall St. last month

ENSC
+5.60%
ENSCW
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced interim ...

ACCESS Newswire 2 months ago

ENSC
+5.60%
ENSCW
ENSC Continues to Announce Potential Life-Changing Results

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing treatments designed to have the same pain-relieving capabilities as opioids but come with the ability to inhibit abuse and overdoses. Opioid abuse is a national crisis, with the CDC estimating over 75,000 deaths from opioid overdoses and there are

Zacks Small Cap Research 2 months ago

ENSCW
Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today issued a letter to shareholders ...

ACCESS Newswire 2 months ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on December ...

ACCESS Newswire 3 months ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the receipt ...

ACCESS Newswire 3 months ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...

ACCESS Newswire 3 months ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...

ACCESS Newswire 3 months ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it ...

ACCESS Newswire 4 months ago

ENSC
+5.60%
ENSCW
Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations

Ensysce Biosciences ( NASDAQ:ENSC ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.42m (up by US$2.98m...

Simply Wall St. 4 months ago

ENSC
+5.60%
ENSCW
ENSC Improves Position

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) released its 3Q2024 results that showed a much improved cash balance of $4.2 million due in large part to the grant described below and some financial offerings which we have detailed in the past. The company continues to make progress, but notes that future revenue will likely be lower than

Zacks Small Cap Research 4 months ago

ENSCW

Performance Overview

Return	ENSC	S&P 500 (^GSPC)
YTD	-67.57%	-3.58%
1-Year	-78.27%	+8.94%
3-Year	-99.93%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations

ENSC Starts 2025 in Great Shape

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)?

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

ENSC Continues to Announce Potential Life-Changing Results

Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations

ENSC Improves Position

Performance Overview